• Je něco špatně v tomto záznamu ?

HE4 and ROMA index in Czech postmenopausal women

Z. Novotny, J. Presl, R. Kucera, O. Topolcan, J. Vrzalova, R. Fuchsova, L. Betincova, Z. Rokyta,

. 2012 ; 32 (9) : 4137-40.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13012444

AIM: The first aim of the project was to evaluate the benefits of the determination of human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) index for primary detection of ovarian cancer in a population of Czech women. The second aim was to study the advantages HE4, cancer antigen 125 (CA125) and ROMA index for distinguishing between benign and malignant tumors. Aware of the age distribution of ovarian cancer, we focused on postmenopausal patients. PATIENTS AND METHODS: Our group of patients consisted of 256 females, 21 with ovarian cancer and 235 with benign ovarian tumors. All diagnoses were histologically verified. We determined the serum levels of HE4 and CA125 and calculated the ROMA2 index for postmenopausal women. Serum levels of the analytes were measured using an Architect 1000i instrument. Serum samples were collected prior to surgery or any other form of treatment and the results of the two groups of patients were compared (malignant vs. benign). RESULTS: There was a significant difference in the serum levels for all parameters studied between the groups of patients with malignant and those with benign diagnoses (Wilcoxon test, p<0.0001). When all parameters were evaluated at 95% specificity, the HE4 cut-off was 112 pmol/l at a sensitivity of 71.42%, a positive predictive value (PPV) of 55.56%, a negative predictive value (NPV) of 97.14% and an area under the curve (AUC) of 0.9152. The CA125 cut-off was 81 IU/l at a sensitivity of 80.95%, a PPV of 58.62%, a NPV of 98.23% and an AUC of 0.9731. ROMA2 index had a cut-off 37.70% at a sensitivity of 85.71%, a PPV of 62.06%, a NPV of 98.65% and an AUC of 0.9803. The highest diagnostic efficiency was achieved by the ROMA2 index. CONCLUSION: Determination of HE4 along with CA125 and ROMA2 index calculation is a suitable method for the improvement of the primary detection of ovarian cancer. This approach also improves the differential diagnostic possibilities for distinguishing between malignant and benign tumors.

000      
00000naa a2200000 a 4500
001      
bmc13012444
003      
CZ-PrNML
005      
20130408112238.0
007      
ta
008      
130404s2012 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)22993374
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Novotny, Zdenek $u Department of Gynecology and Obstetrics, Faculty Hospital in Pilsen, Pilsen, Czech Republic.
245    10
$a HE4 and ROMA index in Czech postmenopausal women / $c Z. Novotny, J. Presl, R. Kucera, O. Topolcan, J. Vrzalova, R. Fuchsova, L. Betincova, Z. Rokyta,
520    9_
$a AIM: The first aim of the project was to evaluate the benefits of the determination of human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) index for primary detection of ovarian cancer in a population of Czech women. The second aim was to study the advantages HE4, cancer antigen 125 (CA125) and ROMA index for distinguishing between benign and malignant tumors. Aware of the age distribution of ovarian cancer, we focused on postmenopausal patients. PATIENTS AND METHODS: Our group of patients consisted of 256 females, 21 with ovarian cancer and 235 with benign ovarian tumors. All diagnoses were histologically verified. We determined the serum levels of HE4 and CA125 and calculated the ROMA2 index for postmenopausal women. Serum levels of the analytes were measured using an Architect 1000i instrument. Serum samples were collected prior to surgery or any other form of treatment and the results of the two groups of patients were compared (malignant vs. benign). RESULTS: There was a significant difference in the serum levels for all parameters studied between the groups of patients with malignant and those with benign diagnoses (Wilcoxon test, p<0.0001). When all parameters were evaluated at 95% specificity, the HE4 cut-off was 112 pmol/l at a sensitivity of 71.42%, a positive predictive value (PPV) of 55.56%, a negative predictive value (NPV) of 97.14% and an area under the curve (AUC) of 0.9152. The CA125 cut-off was 81 IU/l at a sensitivity of 80.95%, a PPV of 58.62%, a NPV of 98.23% and an AUC of 0.9731. ROMA2 index had a cut-off 37.70% at a sensitivity of 85.71%, a PPV of 62.06%, a NPV of 98.65% and an AUC of 0.9803. The highest diagnostic efficiency was achieved by the ROMA2 index. CONCLUSION: Determination of HE4 along with CA125 and ROMA2 index calculation is a suitable method for the improvement of the primary detection of ovarian cancer. This approach also improves the differential diagnostic possibilities for distinguishing between malignant and benign tumors.
650    _2
$a věkové faktory $7 D000367
650    _2
$a algoritmy $7 D000465
650    _2
$a antigen CA-125 $x krev $7 D018394
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a membránové proteiny $x krev $7 D008565
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nemoci ovaria $x krev $7 D010049
650    _2
$a nádory vaječníků $x krev $7 D010051
650    _2
$a postmenopauza $x krev $7 D017698
650    _2
$a proteiny $x metabolismus $7 D011506
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Presl, Jiri $u -
700    1_
$a Kucera, Radek $u -
700    1_
$a Topolcan, Ondrej $u -
700    1_
$a Vrzalova, Jindra $u -
700    1_
$a Fuchsova, Radka $u -
700    1_
$a Betincova, Lucie $u -
700    1_
$a Rokyta, Zdenek $u -
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 32, č. 9 (2012), s. 4137-40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22993374 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130408112504 $b ABA008
999    __
$a ok $b bmc $g 975642 $s 810725
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 32 $c 9 $d 4137-40 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20130404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...